Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

PURPOSE: Immunotherapies targeting PD-1/L1 enhance pathologic complete response (pCR) rates when added to standard neoadjuvant chemotherapy (NAC) regimens in early-stage triple-negative, and possibly high-risk estrogen receptor–positive breast cancer. However, immunotherapy has been associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Ericsson, Paula I., Wulfkhule, Julia D., Gallagher, Rosa I., Sun, Xiaopeng, Axelrod, Margaret L., Sheng, Quanhu, Luo, Na, Gomez, Henry, Sanchez, Violeta, Sanders, Melinda, Pusztai, Lajos, Petricoin, Emanuel, Blenman, Kim R.M., Balko, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792110/
https://www.ncbi.nlm.nih.gov/pubmed/34315723
http://dx.doi.org/10.1158/1078-0432.CCR-21-0607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792110/
https://www.ncbi.nlm.nih.gov/pubmed/34315723
http://dx.doi.org/10.1158/1078-0432.CCR-21-0607

Ejemplares similares